PLD5

Summary

PLD5 (phospholipase D family member 5, HGNC:26879) is a protein-coding gene on chromosome 1q43, encoding Inactive phospholipase D5 (Q8N7P1).

Predicted to enable catalytic activity. Predicted to be located in membrane.

Source: NCBI Gene 200150 — RefSeq curated summary.

At a glance

• GWAS associations: 12
• Clinical variants (ClinVar): 62 total — 1 pathogenic
• MANE Select transcript: NM_001372062

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:26879
Approved symbol	PLD5
Name	phospholipase D family member 5
Location	1q43
Locus type	gene with protein product
Status	Approved
Aliases	FLJ40773
Ensembl gene	ENSG00000180287
Ensembl biotype	protein_coding
Entrez	200150

Gene structure

Transcript identifiers

Ensembl transcripts: 8 — 4 protein_coding, 3 nonsense_mediated_decay, 1 protein_coding_CDS_not_defined

ENST00000314833, ENST00000366545, ENST00000427495, ENST00000442594, ENST00000459864, ENST00000467561, ENST00000474177, ENST00000536534

RefSeq mRNA: 4 — MANE Select: NM_001372062 NM_001195811, NM_001195812, NM_001320272, NM_001372062

CCDS: CCDS1621, CCDS55692

Canonical transcript exons

ENST00000536534 — 10 exons

Exon	Start	End
ENSE00001693014	242348106	242348242
ENSE00002232503	242524088	242524697
ENSE00002251260	242082986	242090110
ENSE00003467373	242288362	242288530
ENSE00003543513	242107671	242107839
ENSE00003561881	242100668	242100782
ENSE00003572023	242219988	242220115
ENSE00003574708	242113890	242114026
ENSE00003662482	242124468	242124665
ENSE00003788416	242265337	242265448

Expression profiles

Bgee: expression breadth ubiquitous, 167 present calls, max score 98.28.

FANTOM5 (CAGE): breadth broad, TPM avg 3.4256 / max 361.1749, expressed in 593 samples.

FANTOM5 promoters (9 alternative TSS)

Promoter ID	TPM avg	Samples expressed
18317	1.6134	465
18310	0.7684	140
18316	0.5957	298
18309	0.1933	91
18311	0.1693	40
18315	0.0366	11
18313	0.0238	5
18312	0.0171	7
18314	0.0079	4

Top tissues by expression

245 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
pigmented layer of retina	UBERON:0001782	98.28	gold quality
descending thoracic aorta	UBERON:0002345	84.24	gold quality
thoracic aorta	UBERON:0001515	83.78	gold quality
ascending aorta	UBERON:0001496	83.60	gold quality
aorta	UBERON:0000947	79.80	gold quality
popliteal artery	UBERON:0002250	76.92	gold quality
tibial artery	UBERON:0007610	76.87	gold quality
cerebellar cortex	UBERON:0002129	76.55	gold quality
cerebellar hemisphere	UBERON:0002245	76.49	gold quality
cerebellum	UBERON:0002037	75.88	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	75.55	silver quality
right hemisphere of cerebellum	UBERON:0014890	74.73	gold quality
endothelial cell	CL:0000115	73.96	silver quality
C1 segment of cervical spinal cord	UBERON:0006469	73.75	gold quality
prefrontal cortex	UBERON:0000451	73.33	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	72.68	silver quality
corpus callosum	UBERON:0002336	72.34	gold quality
spinal cord	UBERON:0002240	71.27	gold quality
adrenal tissue	UBERON:0018303	70.63	gold quality
right coronary artery	UBERON:0001625	69.79	gold quality
anterior cingulate cortex	UBERON:0009835	69.29	gold quality
hypothalamus	UBERON:0001898	68.50	gold quality
amygdala	UBERON:0001876	68.20	gold quality
substantia nigra	UBERON:0002038	67.75	gold quality
adenohypophysis	UBERON:0002196	67.75	gold quality
frontal cortex	UBERON:0001870	66.94	gold quality
frontal lobe	UBERON:0016525	66.94	gold quality
neocortex	UBERON:0001950	66.79	gold quality
left coronary artery	UBERON:0001626	66.73	gold quality
Brodmann (1909) area 9	UBERON:0013540	66.64	gold quality

Single-cell (SCXA)

Detected in 5 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-GEOD-135922	yes	13.13
E-MTAB-8060	no	174.62
E-GEOD-124858	no	47.20
E-MTAB-10137	no	4.76
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

112 targeting PLD5, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-656-3P	100.00	72.15	2788
HSA-MIR-3924	100.00	72.09	2394
HSA-MIR-6833-3P	100.00	70.63	3197
HSA-MIR-4768-5P	100.00	69.49	2861
HSA-MIR-4668-3P	100.00	68.74	2635
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-196A-1-3P	99.99	72.15	2772
HSA-MIR-223-3P	99.99	70.14	1140
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-3667-3P	99.99	67.17	1636
HSA-MIR-568	99.98	69.86	2084
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-607	99.97	73.62	5593
HSA-MIR-548AJ-3P	99.96	73.38	5345
HSA-MIR-548X-3P	99.96	73.38	5345
HSA-MIR-590-3P	99.96	74.34	6478
HSA-MIR-6845-3P	99.94	66.88	1439
HSA-MIR-548J-3P	99.94	72.61	4881
HSA-MIR-9718	99.94	68.91	918
HSA-MIR-548AE-3P	99.93	72.66	4867
HSA-MIR-548AH-3P	99.93	72.54	4872
HSA-MIR-548AM-3P	99.93	72.54	4872
HSA-MIR-548AQ-3P	99.93	72.66	4867
HSA-MIR-335-3P	99.93	73.36	4958
HSA-MIR-218-5P	99.93	72.22	2103
HSA-MIR-6508-5P	99.92	70.67	2465
HSA-MIR-7-1-3P	99.91	71.53	4384
HSA-MIR-7-2-3P	99.91	71.40	4394

Literature-anchored findings (GeneRIF, showing 1)

• MicroRNA miR-145-5p inhibits Phospholipase D 5 (PLD5) to downregulate cell proliferation and metastasis to mitigate prostate cancer. (PMID:34238129)

Cross-species orthologs

9 orthologs

Organism	Symbol	Gene ID
danio_rerio	pld5	ENSDARG00000063257
mus_musculus	Pld5	ENSMUSG00000055214
rattus_norvegicus	Pld5	ENSRNOG00000003997
drosophila_melanogaster	Pld3	FBGN0032923
drosophila_melanogaster	CG43345	FBGN0263050
caenorhabditis_elegans		WBGENE00013080
caenorhabditis_elegans		WBGENE00017124
caenorhabditis_elegans		WBGENE00017316
caenorhabditis_elegans		WBGENE00020256

Paralogs (2): PLD3 (ENSG00000105223), PLD4 (ENSG00000166428)

Protein

Protein identifiers

Inactive phospholipase D5 — Q8N7P1 (reviewed: Q8N7P1)

Alternative names: Inactive choline phosphatase 5, Inactive phosphatidylcholine-hydrolyzing phospholipase D5, PLDc

All UniProt accessions (5): Q8N7P1, F5GXZ8, F5H329, F8W7H1, J3KP61

UniProt curated annotations — full annotation on UniProt →

Subcellular location. Membrane.

Similarity. Belongs to the phospholipase D family.

Isoforms (4)

UniProt ID	Names	Canonical?
Q8N7P1-1	1	yes
Q8N7P1-2	2
Q8N7P1-3	3
Q8N7P1-4	4

RefSeq proteins (4): NP_001182740, NP_001182741, NP_001307201, NP_001358991* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001736	PLipase_D/transphosphatidylase	Domain
IPR032803	PLDc_3	Domain
IPR050874	Diverse_PLD-related	Family

Pfam: PF13918

UniProt features (10 total): splice variant 4, domain 2, glycosylation site 2, chain 1, transmembrane region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8N7P1-F1	83.26	0.62

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Glycosylation sites (2): 121, 302

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 78 (showing top): GSE45365_NK_CELL_VS_BCELL_DN, RNGTGGGC_UNKNOWN, chr1q43, TGTYNNNNNRGCARM_UNKNOWN, ER_Q6_02, AAGCACA_MIR218, YNTTTNNNANGCARM_UNKNOWN, MEISSNER_BRAIN_HCP_WITH_H3K4ME3_AND_H3K27ME3, MEISSNER_NPC_HCP_WITH_H3K4ME2_AND_H3K27ME3, EGR_Q6, ICSBP_Q6, GSE14415_ACT_VS_CTRL_NATURAL_TREG_UP, E2F1_Q6_01, MIR607, MIR548AJ_3P_MIR548X_3P

GO Biological Process (0):

GO Molecular Function (1): catalytic activity (GO:0003824)

GO Cellular Component (1): membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
molecular_function	1
cellular anatomical structure	1

Protein interactions and networks

STRING

576 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
PLD5	PLD6	Q8N2A8	712
PLD5	PLD2	O14939	640
PLD5	WDR64	B1ANS9	499
PLD5	PNPLA8	Q9NP80	433
PLD5	FAR2	Q96K12	418
PLD5	SVOPL	Q8N434	405
PLD5	NPSR1	Q6W5P4	399
PLD5	EIF1	P41567	398
PLD5	STEEP1	Q9H5V9	397
PLD5	ARHGAP25	P42331	396
PLD5	RPL10A	P52859	389
PLD5	HNRNPA1L2	Q32P51	382
PLD5	LHFPL4	Q7Z7J7	381
PLD5	FUNDC2	Q9BWH2	374
PLD5	TTBK2	Q6IQ55	373

IntAct

5 interactions, top by confidence:

A	B	Type	Score
FBXO2	TMEM131L	psi-mi:“MI:0914”(association)	0.530
PLD5	MACROH2A1	psi-mi:“MI:0914”(association)	0.350
CLGN	TMEM131L	psi-mi:“MI:0914”(association)	0.350
INPP5K	UBR5	psi-mi:“MI:0914”(association)	0.350

BioGRID (59): PLD5 (Synthetic Lethality), LRRC15 (Affinity Capture-MS), SERPINA3 (Affinity Capture-MS), ATG9B (Affinity Capture-MS), CALML3 (Affinity Capture-MS), HEPHL1 (Affinity Capture-MS), TGM3 (Affinity Capture-MS), TGM1 (Affinity Capture-MS), HIST2H3PS2 (Affinity Capture-MS), ARL8B (Affinity Capture-MS), DSG4 (Affinity Capture-MS), S100A3 (Affinity Capture-MS), VSIG8 (Affinity Capture-MS), CALML5 (Affinity Capture-MS), ENGASE (Affinity Capture-MS)

ESM2 similar proteins: A0A7H0DN15, A0A7H0DN30, A2RSQ1, A5D7B7, B2D0J5, C0HLL4, O17405, O57179, P04021, P18377, P20537, P20638, P26653, P29885, P33815, P35501, P36316, P49713, P55939, P58766, P86387, P86875, P91406, P97321, Q09706, Q10916, Q12884, Q21389, Q38882, Q3UNN8, Q3UPY5, Q54K50, Q54K56, Q54SA1, Q54SR8, Q5XIL5, Q60V90, Q640B3, Q6L6S1, Q6PB03

Diamond homologs: A0A7H0DN15, O17405, O35405, P18377, P20537, Q2KJJ8, Q3UNN8, Q4R583, Q54K50, Q54SA1, Q5FVH2, Q5R4Y7, Q640B3, Q6PB03, Q8BG07, Q8IV08, Q8N7P1, Q96BZ4, P36316, P26579, P63800, P63801, P63802, Q5HEB2, Q5HMD3, Q6G7M2, Q6GEY7, Q8CNK3

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

62 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	0
Uncertain significance	47
Likely benign	5
Benign	1

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
689438	Single allele	Pathogenic

SpliceAI

4492 predictions. Top by Δscore:

Variant	Effect	Δscore
1:242100780:TTT:T	acceptor_gain	1.0000
1:242107856:C:CT	acceptor_gain	1.0000
1:242113886:TGACC:T	donor_loss	1.0000
1:242113887:GAC:G	donor_loss	1.0000
1:242113888:A:AG	donor_loss	1.0000
1:242219982:GCTTA:G	donor_loss	1.0000
1:242219983:CTTA:C	donor_loss	1.0000
1:242219984:TTAC:T	donor_loss	1.0000
1:242219985:TA:T	donor_loss	1.0000
1:242219986:A:C	donor_loss	1.0000
1:242265335:AC:A	donor_gain	1.0000
1:242265336:CC:C	donor_gain	1.0000
1:242265447:CC:C	acceptor_gain	1.0000
1:242265448:CC:C	acceptor_gain	1.0000
1:242265449:C:CC	acceptor_gain	1.0000
1:242288532:T:C	acceptor_gain	1.0000
1:242288543:T:C	acceptor_gain	1.0000
1:242288543:T:TC	acceptor_gain	1.0000
1:242288544:T:C	acceptor_gain	1.0000
1:242288544:T:TC	acceptor_gain	1.0000
1:242348105:CCGA:C	donor_gain	1.0000
1:242348238:TGGGA:T	acceptor_gain	1.0000
1:242348240:GGA:G	acceptor_gain	1.0000
1:242348241:GA:G	acceptor_gain	1.0000
1:242348243:C:CC	acceptor_gain	1.0000
1:242348243:C:T	acceptor_loss	1.0000
1:242524086:A:AC	donor_gain	1.0000
1:242524087:C:CC	donor_gain	1.0000
1:242524087:CGTG:C	donor_gain	1.0000
1:242524105:T:A	donor_gain	1.0000

AlphaMissense

3558 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
1:242348203:A:G	C77R	1.000
1:242348206:A:G	C76R	1.000
1:242124552:C:A	W283C	0.999
1:242124552:C:G	W283C	0.999
1:242124554:A:G	W283R	0.999
1:242124554:A:T	W283R	0.999
1:242288417:A:T	V147D	0.999
1:242348196:G:T	A79D	0.999
1:242348214:G:T	A73D	0.999
1:242124616:T:A	D262V	0.998
1:242220044:C:G	D227H	0.998
1:242220053:A:G	W224R	0.998
1:242220053:A:T	W224R	0.998
1:242348181:A:G	L84P	0.998
1:242348184:G:T	A83E	0.998
1:242348211:A:G	L74P	0.998
1:242089995:A:C	F490L	0.997
1:242089995:A:T	F490L	0.997
1:242089997:A:G	F490L	0.997
1:242090008:A:G	L486P	0.997
1:242090099:A:G	W456R	0.997
1:242090099:A:T	W456R	0.997
1:242124616:T:G	D262A	0.997
1:242124617:C:G	D262H	0.997
1:242124633:G:C	C256W	0.997
1:242124635:A:G	C256R	0.997
1:242220043:T:A	D227V	0.997
1:242089983:C:A	W494C	0.996
1:242089983:C:G	W494C	0.996
1:242090059:A:G	L469P	0.996

dbSNP variants (sampled 300 via entrez): RS1000000350 (1:242220629 T>G), RS1000012708 (1:242202645 T>G), RS1000026077 (1:242426707 C>T), RS1000026176 (1:242103196 T>C), RS1000027212 (1:242461559 C>T), RS1000031600 (1:242220851 C>T), RS1000034220 (1:242125891 A>G), RS1000047255 (1:242434341 G>C), RS1000049689 (1:242511242 T>C), RS1000050957 (1:242508897 G>A), RS1000052537 (1:242379643 C>T), RS1000054054 (1:242267813 T>C), RS1000065661 (1:242212512 G>A,T), RS1000066732 (1:242238569 G>A), RS1000068226 (1:242173610 A>G)

Disease associations

OMIM: gene `` | disease phenotypes: MIM:150800

GenCC curated gene-disease

Mondo (3): primary ovarian failure (MONDO:0005387), hereditary leiomyomatosis and renal cell cancer (MONDO:0007888), hereditary neoplastic syndrome (MONDO:0015356)

Orphanet (3): Inherited cancer-predisposing syndrome (Orphanet:140162), Hereditary leiomyomatosis and renal cell cancer (Orphanet:523), NON RARE IN EUROPE: Primary ovarian failure (Orphanet:619)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

12 associations (top):

Study	Trait	p-value
GCST001762_833	Obesity-related traits	1.000000e-06
GCST002097_30	Coronary artery calcification	7.000000e-06
GCST002198_7	Tuberculosis	8.000000e-07
GCST002345_5	Response to cytadine analogues (cytosine arabinoside)	9.000000e-06
GCST003016_1	Hypersomnia during a major depressive episode in bipolar disorder	6.000000e-06
GCST004749_55	Lung cancer in ever smokers	8.000000e-08
GCST006088_13	Familial squamous cell lung carcinoma	2.000000e-06
GCST006291_124	Spherical equivalent or myopia (age of diagnosis)	1.000000e-14
GCST008027_3	Smoking behaviour (cigarettes smoked per day)	3.000000e-08
GCST008027_4	Smoking behaviour (cigarettes smoked per day)	2.000000e-06
GCST008758_27	Pre-treatment viral load in HIV-1 infection	7.000000e-21
GCST010397_15	Gut microbiota (bacterial taxa, rank normal transformation method)	1.000000e-06

EFO canonical traits (8, from GWAS)

EFO ID	Trait name
EFO:0004697	estradiol measurement
EFO:0004723	coronary artery calcification
EFO:0007634	major depressive episode
EFO:0006953	family history of lung cancer
EFO:0004847	age at onset
EFO:0006525	cigarettes per day measurement
EFO:0010125	viral load
EFO:0007874	gut microbiome measurement

MeSH disease descriptors (3)

Descriptor	Name	Tree numbers
D009386	Neoplastic Syndromes, Hereditary	C04.700; C16.320.700
D016649	Primary Ovarian Insufficiency	C12.050.351.500.056.630.750; C12.100.250.056.630.750; C19.391.630.750
C535516	Hereditary leiomyomatosis and renal cell cancer (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

51 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	increases mutagenesis, affects methylation, increases methylation	3
entinostat	decreases expression, affects cotreatment	2
belinostat	decreases expression, affects cotreatment	2
Estradiol	affects cotreatment, increases expression	2
p-Chloromercuribenzoic Acid	affects cotreatment, decreases expression	2
methylmercuric chloride	decreases expression	1
bisphenol A	affects cotreatment, increases methylation	1
lead acetate	increases expression	1
sodium arsenate	increases abundance, increases expression	1
trichostatin A	decreases expression	1
3,4-dichloroaniline	increases expression	1
sodium arsenite	increases expression	1
butyraldehyde	decreases expression	1
benzo(e)pyrene	affects methylation	1
aflatoxin B2	decreases methylation	1
cupric chloride	increases expression	1
beta-methylcholine	affects expression	1
CGP 52608	affects binding, increases reaction	1
perfluoro-n-nonanoic acid	decreases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
nutlin 3	increases expression	1
abrine	decreases expression	1
dorsomorphin	affects cotreatment, decreases expression	1
bisphenol S	decreases methylation	1
jinfukang	increases expression, affects cotreatment	1
incobotulinumtoxinA	decreases expression	1
Resveratrol	affects cotreatment, decreases expression	1
Sunitinib	decreases expression	1
Zoledronic Acid	increases expression	1
Arsenic Trioxide	decreases expression	1

Cellosaurus cell lines

2 cell lines: 2 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_TE49	HAP1 PLD5 (-) 1	Cancer cell line	Male
CVCL_TE50	HAP1 PLD5 (-) 2	Cancer cell line	Male

Clinical trials (associated diseases)

112 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00417066	PHASE4	COMPLETED	Flexible GnRH Antagonist vs Flare up GnRH Agonist Protocol in Poor Responders
NCT00732693	PHASE4	COMPLETED	Evaluation of Physiologic and Standard Sex Steroid Replacement Regimens in Women With Premature Ovarian Failure
NCT00837616	PHASE4	COMPLETED	Estrogen Dosing in Turner Syndrome: Pharmacology and Metabolism
NCT01853501	PHASE4	UNKNOWN	Effects of ADSC Therapy in Women With POF
NCT02783937	PHASE4	COMPLETED	Filgrastim for Premature Ovarian Insufficiency
NCT03535480	PHASE4	UNKNOWN	Autologous Bone Marrow Stem Cell Ovarian Transplantation to Restore Ovarian Function in Premature Ovarian Failure
NCT00140998	PHASE3	COMPLETED	Estrogen Treatment (Oral vs. Patches) in Turner Syndrome
NCT00001951	PHASE2	COMPLETED	Hormone Replacement in Young Women With Premature Ovarian Failure
NCT00370019	PHASE2	WITHDRAWN	Effects of an Estrogen Replacement Therapy Skin Patch on Ovulation in Women With Premature Ovarian Failure
NCT00429494	PHASE2	COMPLETED	GnRH Analogue for Ovarian Function Preservation in Hematopoietic Stem Cell Transplantation Patients
NCT03816852	PHASE2	SUSPENDED	The Safety and Efficiency Study of Mesenchymal Stem Cell (19#iSCLife®-POI) in Premature Ovarian Insufficiency
NCT04536467	PHASE2	UNKNOWN	Prevention of Chemotherapy-Induced Ovarian Failure With Goserelin in Premenopausal Lymphoma Patients
NCT06117982	PHASE2	COMPLETED	The Impact of Granulocyte Colony Stimulating Factor on Premature Ovarian Insufficiency
NCT00971620	PHASE2	COMPLETED	Randomized Pilot Study for the Treatment of Cutaneous Leiomyomas With Botulinum Toxin
NCT01130519	PHASE2	COMPLETED	A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer
NCT04603365	PHASE2	WITHDRAWN	Pamiparib and Temozolomide for the Treatment of Hereditary Leiomyomatosis and Renal Cell Cancer
NCT04981509	PHASE2	RECRUITING	Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer
NCT02912104	PHASE1	COMPLETED	A Therapeutic Trial of Human Amniotic Epithelial Cells Transplantation for Primary Ovarian Failure
NCT03178695	PHASE1	COMPLETED	Inovium Ovarian Rejuvenation Trials
NCT04815213	PHASE1	ACTIVE_NOT_RECRUITING	The Use of Expandeded Mesenchymal Stromal Cells (MSC) in Premature Ovarian Failure (POF) in Adult Humans
NCT05138367	PHASE1	COMPLETED	Effects of UCA-PSCs in Women With POF
NCT06132542	PHASE1	UNKNOWN	Autologous ADMSC Transplantation in Patients With POI
NCT00948857	PHASE2/PHASE3	TERMINATED	Dehydroepiandrosterone (DHEA) Treatment and Premature Ovarian Failure (POF)
NCT04031456	PHASE2/PHASE3	RECRUITING	Autologous PRP Infusion May Restore Ovarian Function and May Promote Folliculogenesis in POI Patients
NCT02043743	PHASE1/PHASE2	UNKNOWN	Autologous Stem Cells Transplantation in Patients With Idiopathic and Drug Induced Premature Ovarian Failure
NCT02062931	PHASE1/PHASE2	UNKNOWN	Autologous Mesenchymal Stem Cells Transplantation In Women With Premature Ovarian Failure
NCT02151890	PHASE1/PHASE2	COMPLETED	Pregnancy After Stem Cell Transplantation in Premature Ovarian Failure
NCT02372474	PHASE1/PHASE2	COMPLETED	It is a Real The First Baby Of Autologous Stem Cell Therapy in Premature Ovarian Failure
NCT02603744	PHASE1/PHASE2	UNKNOWN	Autologous Adipose Derived Mesenchymal Stromal Cells Transplantation in Women With Premature Ovarian Failure (POF)
NCT02644447	PHASE1/PHASE2	COMPLETED	Transplantation of HUC-MSCs With Injectable Collagen Scaffold for POF
NCT03069209	PHASE1/PHASE2	UNKNOWN	Autologous Bone Marrow-Derived Stem Cell Transplantation in Patients With Premature Ovarian Failure (POF)
NCT03985462	PHASE1/PHASE2	WITHDRAWN	Very Small Embryonic-like Stem Cells for Ovary
NCT04009473	PHASE1/PHASE2	UNKNOWN	Stem Cell Therapy and Growth Factor Ovarian in Vitro Activation
NCT04071574	PHASE1/PHASE2	COMPLETED	Comparative Study on the Efficacy of Ovarian Stimulation Protocols on the Success Rate of ICSI in Female Infertility
NCT04922398	PHASE1/PHASE2	UNKNOWN	Ovarian Injection of PRP (Platelet -Rich Plasma) Vs Normal Saline in Premature Ovarian Insufficiency
NCT05462379	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	Autologous Heterotopic Fresh Ovarian Graft in Woman With LACC Eligible for Pelvic Radiotherapy Treatment.
NCT06202547	PHASE1/PHASE2	UNKNOWN	Intra-ovarian Injection of MSC-EVs in Idiopathic Premature Ovarian Failure
NCT01129947	EARLY_PHASE1	WITHDRAWN	The Use of DHEA in Women With Premature Ovarian Failure
NCT05522634	EARLY_PHASE1	UNKNOWN	A Clinical Study of Chinese Herbal Compound TJAOA101 in the Treatment of Premature Ovarian Insufficiency
NCT07308327	EARLY_PHASE1	ACTIVE_NOT_RECRUITING	The Influence of Gut Microbiota on Ovarian Function: A Single-center, Randomized,Double Blind, Parallel-controlled, Exploratory Clinical Trial